The effect of the JAK2 inhibitor TG101209 against T cell acute lymphoblastic leukemia (T-ALL) is mediated by inhibition of JAK-STAT signaling and activation of the crosstalk between apoptosis and autophagy signaling

Previous reports have shown that active JAK2 contributes to T cell acute lymphoblastic leukaemia (T-ALL) development and that JAK inhibitors may be a potential treatment for T-ALL. In the current study, the JAK2 inhibitor TG101209 was used to treat T-ALL cell lines and primary T-ALL cells. The effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Zhao, Yi, Yifang, Xie, Sisi, Yu, Haizhi, Peng, Hongling, Zhang, Guangsen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739771/
https://www.ncbi.nlm.nih.gov/pubmed/29290986
http://dx.doi.org/10.18632/oncotarget.22053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739771/
https://www.ncbi.nlm.nih.gov/pubmed/29290986
http://dx.doi.org/10.18632/oncotarget.22053

Ejemplares similares